Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
China channel feed
Lilly Asian Ventures backs Impact's PARP research again, chipping in for $30M Series C led by Decheng Capital
7 years ago
Financing
BeiGene bags a staggering $903M IPO on the HKEX — and still manages to spark some nervous fretting
7 years ago
Financing
Ascletis breaks into HKEX, briefly rising on hotly anticipated public debut of first biotech
7 years ago
Financing
Fresh out of 6 Dimensions' incubator, Curon launches with $150M and backing from Boyu, Temasek
7 years ago
Financing
In for the China biotech gold rush, BeiGene eyes monster $800M-plus Hong Kong IPO
7 years ago
Financing
Ascletis reaps record $400M from Hong Kong investors in the exchange's first-ever pre-revenue biotech listing
7 years ago
Financing
Pre-revenue vaccine developer CanSino lines up at a buzzing HKEX
7 years ago
Financing
On its way to making Hong Kong history, Ascletis eyes $457M haul in GIC-backed IPO
7 years ago
Financing
Fast-growing Ascentage has big plans for its latest $150M raise -- but what about the IPO?
7 years ago
Financing
12 top China VCs you need to know who are making a transpacific splash (Part 2)
7 years ago
Financing
Special
China's Tasly Biopharma turns a development partner into an investor as it preps Hong Kong IPO
7 years ago
Pharma
7 things you need to know now about raising biotech cash in China (Part 1)
7 years ago
Financing
Another IPO frenzy? Two US biotechs head to Hong Kong for a public market debut
7 years ago
Financing
Hong Kong exchange picks up steam with two biotech IPOs from Innovent, MicuRx
7 years ago
Financing
Sanofi gets serious in China with plans to hire 300 for $76M R&D site in Chengdu
7 years ago
R&D
Forget the biotech mega-round. Try the $200M-plus China 'ultra' on for size
7 years ago
Financing
C-Bridge hands Nuance Biotech $35M, opening doors to more China licensing deals
7 years ago
Financing
R&D
Latest ranking of top research institutions show China coming on strong — with significant implications for biotech
7 years ago
R&D
With an AstraZeneca cancer drug in one hand, $37M in the other, Shanghai's Alpha Bio zooms into a PhII study
7 years ago
Financing
Startups
High-profile Chinese investor Vincent Cheung plays a lead role in raising $100M round for a Boston start-up
7 years ago
Financing
A functional HIV cure? We have a long way to go, but Hong Kong investigators find a spotlight for their preclinical antibody
7 years ago
Discovery
Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK
7 years ago
Pharma
AI team at Insilico gets some major league backing from China as Alex Zhavoronkov builds global network
7 years ago
Financing
AI
Sound familiar? China/US biotech hybrid lands rights to cancer drugs, cash and a team of development vets to launch Oncologie
7 years ago
Financing
Startups
First page
Previous page
23
24
25
26
27
28
29
Next page
Last page